Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations

Riccardo Lencioni, Thierry De Baere, Marta Burrel, James G. Caridi, Johannes Lammer, Katerina Malagari, Robert C G Martin, Elizabeth O'Grady, Maria Isabel Real, Thomas J. Vogl, Anthony Watkinson, Jean Francois H Geschwind

Research output: Contribution to journalArticle

Abstract

Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized.

Original languageEnglish (US)
Pages (from-to)980-985
Number of pages6
JournalCardioVascular and Interventional Radiology
Volume35
Issue number5
DOIs
StatePublished - Oct 2012

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Pharmaceutical Preparations
Randomized Controlled Trials
Ethiodized Oil
Poisons
Liver
Therapeutics
Standard of Care
Emulsions
Microspheres
Italy
Meta-Analysis
Appointments and Schedules
Oils
Animal Models
Pharmacokinetics
Physicians
Neoplasms

Keywords

  • Chemoembolization
  • Doxorubicin
  • Drug-eluting bead
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX) : Technical recommendations. / Lencioni, Riccardo; De Baere, Thierry; Burrel, Marta; Caridi, James G.; Lammer, Johannes; Malagari, Katerina; Martin, Robert C G; O'Grady, Elizabeth; Real, Maria Isabel; Vogl, Thomas J.; Watkinson, Anthony; Geschwind, Jean Francois H.

In: CardioVascular and Interventional Radiology, Vol. 35, No. 5, 10.2012, p. 980-985.

Research output: Contribution to journalArticle

Lencioni, R, De Baere, T, Burrel, M, Caridi, JG, Lammer, J, Malagari, K, Martin, RCG, O'Grady, E, Real, MI, Vogl, TJ, Watkinson, A & Geschwind, JFH 2012, 'Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations', CardioVascular and Interventional Radiology, vol. 35, no. 5, pp. 980-985. https://doi.org/10.1007/s00270-011-0287-7
Lencioni, Riccardo ; De Baere, Thierry ; Burrel, Marta ; Caridi, James G. ; Lammer, Johannes ; Malagari, Katerina ; Martin, Robert C G ; O'Grady, Elizabeth ; Real, Maria Isabel ; Vogl, Thomas J. ; Watkinson, Anthony ; Geschwind, Jean Francois H. / Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX) : Technical recommendations. In: CardioVascular and Interventional Radiology. 2012 ; Vol. 35, No. 5. pp. 980-985.
@article{57f218ac475a4fcaaade6bf46045960b,
title = "Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX): Technical recommendations",
abstract = "Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized.",
keywords = "Chemoembolization, Doxorubicin, Drug-eluting bead, Hepatocellular carcinoma",
author = "Riccardo Lencioni and {De Baere}, Thierry and Marta Burrel and Caridi, {James G.} and Johannes Lammer and Katerina Malagari and Martin, {Robert C G} and Elizabeth O'Grady and Real, {Maria Isabel} and Vogl, {Thomas J.} and Anthony Watkinson and Geschwind, {Jean Francois H}",
year = "2012",
month = "10",
doi = "10.1007/s00270-011-0287-7",
language = "English (US)",
volume = "35",
pages = "980--985",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded dc bead (DEBDOX)

T2 - Technical recommendations

AU - Lencioni, Riccardo

AU - De Baere, Thierry

AU - Burrel, Marta

AU - Caridi, James G.

AU - Lammer, Johannes

AU - Malagari, Katerina

AU - Martin, Robert C G

AU - O'Grady, Elizabeth

AU - Real, Maria Isabel

AU - Vogl, Thomas J.

AU - Watkinson, Anthony

AU - Geschwind, Jean Francois H

PY - 2012/10

Y1 - 2012/10

N2 - Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized.

AB - Tranarterial chemoembolization (TACE) has been established by a meta-analysis of randomized controlled trials as the standard of care for nonsurgical patients with large or multinodular noninvasive hepatocellular carcinoma (HCC) isolated to the liver and with preserved liver function. Although conventional TACE with administration of an anticancer-in-oil emulsion followed by embolic agents has been the most popular technique, the introduction of embolic drug-eluting beads has provided an alternative to lipiodol-based regimens. Experimental studies have shown that TACE with drug-eluting beads has a safe pharmacokinetic profile and results in effective tumor killing in animal models. Early clinical experiences have confirmed that drug-eluting beads provide a combined ischemic and cytotoxic effect locally with low systemic toxic exposure. Recently, the clinical value of a TACE protocol performed by using the embolic microsphere DC Bead loaded with doxorubicin (DEBDOX; drug-eluting bead doxorubicin) has been shown by randomized controlled trials. An important limitation of conventional TACE has been the inconsistency in the technique and the treatment schedules. This limitation has hampered the acceptance of TACE as a standard oncology treatment. Doxorubicin-loaded DC Bead provides levels of consistency and repeatability not available with conventional TACE and offers the opportunity to implement a standardized approach to HCC treatment. With this in mind, a panel of physicians took part in a consensus meeting held during the European Conference on Interventional Oncology in Florence, Italy, to develop a set of technical recommendations for the use of DEBDOX in HCC treatment. The conclusions of the expert panel are summarized.

KW - Chemoembolization

KW - Doxorubicin

KW - Drug-eluting bead

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84867579825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867579825&partnerID=8YFLogxK

U2 - 10.1007/s00270-011-0287-7

DO - 10.1007/s00270-011-0287-7

M3 - Article

C2 - 22009576

AN - SCOPUS:84867579825

VL - 35

SP - 980

EP - 985

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 5

ER -